Who are Grazaoprevir/Elbasavir/RBV's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/grazaoprevir-elbasavir-rbv.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Grazaoprevir/Elbasavir/RBV — Competitive Intelligence Brief

Grazaoprevir/Elbasavir/RBV (Grazaoprevir/Elbasavir/RBV) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct-acting antiviral (DAA) combination; NS3/4A protease inhibitor + NS5A inhibitor + nucleoside analog. Area: Virology/Hepatology.

marketed Direct-acting antiviral (DAA) combination; NS3/4A protease inhibitor + NS5A inhibitor + nucleoside analog HCV NS3/4A protease; HCV NS5A protein; viral RNA polymerase Virology/Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

Grazaoprevir/Elbasavir/RBV (Grazaoprevir/Elbasavir/RBV) — The HIV Netherlands Australia Thailand Research Collaboration. Grazoprevir inhibits hepatitis C virus NS3/4A protease while elbasavir inhibits NS5A protein, and ribavirin acts as a nucleoside analog to inhibit viral replication.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Grazaoprevir/Elbasavir/RBV TARGET	Grazaoprevir/Elbasavir/RBV	The HIV Netherlands Australia Thailand Research Collaboration	marketed	Direct-acting antiviral (DAA) combination; NS3/4A protease inhibitor + NS5A inhibitor + nucleoside analog	HCV NS3/4A protease; HCV NS5A protein; viral RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Direct-acting antiviral (DAA) combination; NS3/4A protease inhibitor + NS5A inhibitor + nucleoside analog class)

The HIV Netherlands Australia Thailand Research Collaboration · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Grazaoprevir/Elbasavir/RBV — Competitive Intelligence Brief. https://druglandscape.com/ci/grazaoprevir-elbasavir-rbv. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab